The	O
opioid	B:C0027410
antagonist	I:C0027410
,	O
β-	O
funaltrexamine	I:C0053433
,	O
inhibits	O
lipopolysaccharide	O
-	O
induced	O
neuroinflammation	O
and	O
reduces	O
sickness	O
behavior	O
in	O
mice	O
.	O

The	O
opioid	O
antagonist	I:C0027410
,	O
β-	B:C0053433
funaltrexamine	I:C0053433
,	O
inhibits	O
lipopolysaccharide	O
-	O
induced	O
neuroinflammation	O
and	O
reduces	O
sickness	O
behavior	O
in	O
mice	O
.	O

The	O
opioid	O
antagonist	I:C0027410
,	O
β-	O
funaltrexamine	I:C0053433
,	O
inhibits	O
lipopolysaccharide	B:C0023810
-	O
induced	O
neuroinflammation	O
and	O
reduces	O
sickness	O
behavior	O
in	O
mice	O
.	O

The	O
opioid	O
antagonist	I:C0027410
,	O
β-	O
funaltrexamine	I:C0053433
,	O
inhibits	O
lipopolysaccharide	O
-	O
induced	O
neuroinflammation	O
and	O
reduces	O
sickness	O
behavior	O
in	O
mice	B:C1521751
.	O

Brain	B:C0006119
pathologies	I:C0006119
such	O
as	O
neurodegenerative	O
diseases	I:C0524851
,	O
infection	O
,	O
traumatic	O
brain	I:C0876926
injury	I:C0876926
,	O
and	O
mood	O
disorders	I:C0525045
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

Brain	O
pathologies	I:C0006119
such	O
as	O
neurodegenerative	B:C0524851
diseases	I:C0524851
,	O
infection	O
,	O
traumatic	O
brain	I:C0876926
injury	I:C0876926
,	O
and	O
mood	O
disorders	I:C0525045
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

Brain	O
pathologies	I:C0006119
such	O
as	O
neurodegenerative	O
diseases	I:C0524851
,	O
infection	B:C3714514
,	O
traumatic	O
brain	I:C0876926
injury	I:C0876926
,	O
and	O
mood	O
disorders	I:C0525045
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

Brain	O
pathologies	I:C0006119
such	O
as	O
neurodegenerative	O
diseases	I:C0524851
,	O
infection	O
,	O
traumatic	B:C0876926
brain	I:C0876926
injury	I:C0876926
,	O
and	O
mood	O
disorders	I:C0525045
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

Brain	O
pathologies	I:C0006119
such	O
as	O
neurodegenerative	O
diseases	I:C0524851
,	O
infection	O
,	O
traumatic	O
brain	I:C0876926
injury	I:C0876926
,	O
and	O
mood	B:C0525045
disorders	I:C0525045
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

It	O
is	O
well	O
established	O
that	O
neuroinflammation	O
plays	O
an	O
important	O
role	O
in	O
the	O
etiology	O
and	O
/	O
or	O
manifestation	O
of	O
such	O
disorders	B:C0012634
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	B:C0053433
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	B:C0053433
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	B:C0037080
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	B:C0086418
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	B:C0004112
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	B:C1171362
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	B:C0010813
/	O
chemokines	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta	O
-	I:C0053433
funaltrexamine	I:C0053433
(	O
β	O
-	I:C0053433
FNA	I:C0053433
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	B:C0282554
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	B:C0205100
administered	O
β-	O
FNA	I:C0053433
on	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	O
administered	B:C1533734
β-	O
FNA	I:C0053433
on	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	O
administered	O
β-	B:C0053433
FNA	I:C0053433
on	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	O
administered	O
β-	O
FNA	I:C0053433
on	O
lipopolysaccharide	B:C0023810
(	O
lipopolysaccharide	O
)	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	O
administered	O
β-	O
FNA	I:C0053433
on	O
lipopolysaccharide	O
(	O
lipopolysaccharide	B:C0023810
)	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

Adult	O
male	O
C57BL	B:C1521751
/	I:C1521751
6J	I:C1521751
mice	I:C1521751
were	O
administered	O
β-	O
FNA	I:C0053433
and	O
were	O
then	O
immediately	O
administered	O
bacterial	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
.	O

Adult	O
male	O
C57BL	O
/	I:C1521751
6J	I:C1521751
mice	I:C1521751
were	O
administered	O
β-	B:C0053433
FNA	I:C0053433
and	O
were	O
then	O
immediately	O
administered	O
bacterial	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
.	O

Adult	O
male	O
C57BL	O
/	I:C1521751
6J	I:C1521751
mice	I:C1521751
were	O
administered	O
β-	O
FNA	I:C0053433
and	O
were	O
then	O
immediately	O
administered	B:C1533734
bacterial	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
.	O

Adult	O
male	O
C57BL	O
/	I:C1521751
6J	I:C1521751
mice	I:C1521751
were	O
administered	O
β-	O
FNA	I:C0053433
and	O
were	O
then	O
immediately	O
administered	O
bacterial	O
lipopolysaccharide	B:C0023810
(	O
lipopolysaccharide	O
)	O
.	O

Adult	O
male	O
C57BL	O
/	I:C1521751
6J	I:C1521751
mice	I:C1521751
were	O
administered	O
β-	O
FNA	I:C0053433
and	O
were	O
then	O
immediately	O
administered	O
bacterial	O
lipopolysaccharide	O
(	O
lipopolysaccharide	B:C0023810
)	O
.	O

Following	O
behavioral	B:C1160858
analysis	I:C1160858
plasma	O
and	O
brains	O
were	O
collected	O
.	O

Following	O
behavioral	O
analysis	I:C1160858
plasma	B:C0032105
and	O
brains	O
were	O
collected	O
.	O

Following	O
behavioral	O
analysis	I:C1160858
plasma	O
and	O
brains	B:C0006104
were	O
collected	O
.	O

Levels	O
of	O
interleukin	B:C0021760
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	B:C0021760
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	B:C1313708
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	B:C1313708
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	B:C1452296
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	B:C1452296
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	B:C0014441
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

Levels	O
of	O
interleukin	O
-	I:C0021760
6	I:C0021760
(	O
interleukin	O
-	I:C0021760
6	I:C0021760
)	O
,	O
interferon	O
-γ	I:C1313708
inducible	I:C1313708
protein	I:C1313708
-	I:C1313708
10	I:C1313708
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	I:C1452296
protein	I:C1452296
-	I:C1452296
1	I:C1452296
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
(	O
enzyme	B:C0014441
-	I:C0014441
linked	I:C0014441
immunosorbant	I:C0014441
assay	I:C0014441
)	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	B:C0023810
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	B:C0021760
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	B:C1452296
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	B:C1313708
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	B:C0032105
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	B:C1452296
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	B:C1313708
were	O
elevated	O
in	O
the	O
brain	O
.	O

At	O
24h	O
post	O
-	O
lipopolysaccharide	O
injection	O
,	O
interleukin	O
-6	I:C0021760
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	B:C0006104
.	O

β-	B:C0053433
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
CXCL10	O
and	O
CCL2	O
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

β-	O
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	B:C0023810
-	O
induced	O
CXCL10	O
and	O
CCL2	O
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

β-	O
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
CXCL10	B:C1313708
and	O
CCL2	O
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

β-	O
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
CXCL10	O
and	O
CCL2	B:C1452296
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

β-	O
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
CXCL10	O
and	O
CCL2	O
expression	B:C1171362
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

β-	O
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
CXCL10	O
and	O
CCL2	O
expression	O
in	O
brain	B:C0006104
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

β-	O
FNA	I:C0053433
significantly	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
CXCL10	O
and	O
CCL2	O
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	B:C0032105
.	O

lipopolysaccharide	B:C0023810
-	O
induced	O
sickness	O
behavior	O
,	O
as	O
indicated	O
by	O
a	O
reduction	O
in	O
distance	O
moved	O
,	O
was	O
prevented	O
by	O
β-FNA	O
.	O

lipopolysaccharide	O
-	O
induced	O
sickness	O
behavior	O
,	O
as	O
indicated	O
by	O
a	O
reduction	O
in	O
distance	O
moved	B:C0560560
,	O
was	O
prevented	O
by	O
β-FNA	O
.	O

lipopolysaccharide	O
-	O
induced	O
sickness	O
behavior	O
,	O
as	O
indicated	O
by	O
a	O
reduction	O
in	O
distance	O
moved	O
,	O
was	O
prevented	O
by	O
β-FNA	B:C0053433
.	O

Overall	O
,	O
CXCL10	B:C1313708
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	B:C1171362
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	B:C0006104
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	B:C0003467
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	B:C0021760
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	B:C1452296
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	B:C0032105
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	B:C1313708
and	O
CCL2	O
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	B:C1452296
in	O
the	O
brain	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-	O
like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
interleukin	O
-	I:C0021760
6	I:C0021760
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	B:C0006104
.	O

The	O
reduction	O
in	O
sickness	O
behavior	O
may	O
be	O
in	O
part	O
due	O
to	O
decreased	O
chemokine	B:C0282554
expression	O
in	O
the	O
brain	O
;	O
further	O
examination	O
of	O
the	O
anti-inflammatory	O
and	O
neuroprotective	O
effects	O
of	O
β-FNA	O
is	O
warranted	O
.	O

The	O
reduction	O
in	O
sickness	O
behavior	O
may	O
be	O
in	O
part	O
due	O
to	O
decreased	O
chemokine	O
expression	B:C1171362
in	O
the	O
brain	O
;	O
further	O
examination	O
of	O
the	O
anti-inflammatory	O
and	O
neuroprotective	O
effects	O
of	O
β-FNA	O
is	O
warranted	O
.	O

The	O
reduction	O
in	O
sickness	O
behavior	O
may	O
be	O
in	O
part	O
due	O
to	O
decreased	O
chemokine	O
expression	O
in	O
the	O
brain	B:C0006104
;	O
further	O
examination	O
of	O
the	O
anti-inflammatory	O
and	O
neuroprotective	O
effects	O
of	O
β-FNA	O
is	O
warranted	O
.	O

The	O
reduction	O
in	O
sickness	O
behavior	O
may	O
be	O
in	O
part	O
due	O
to	O
decreased	O
chemokine	O
expression	O
in	O
the	O
brain	O
;	O
further	O
examination	O
of	O
the	O
anti-inflammatory	O
and	O
neuroprotective	O
effects	O
of	O
β-FNA	B:C0053433
is	O
warranted	O
.	O

